We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Athira Pharma Inc | NASDAQ:ATHA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 9.54% | 2.64 | 2.50 | 2.54 | 2.65 | 2.43 | 2.43 | 144,700 | 21:44:28 |
From Apr 2024 to Jun 2024
Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual
The Citizens JMP Life Sciences ConferenceFormat: Fireside Chat Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET Location: New York Hilton Midtown
Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcasts will be available for at least 30 days following the event.
About Athira Pharma, Inc.Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, (formerly known as Twitter), and Instagram.
Investor Contacts:Julie RathbunAthira PharmaJulie.rathbun@athira.com206-769-9219
Anne Marie FieldsStern Investor Relationsannemarie.fields@sternir.com 332-213-1956
Media Contact: Janine BogrisInizio Evoke CommsJanine.bogris@inizioevoke.com 201-245-6838
1 Year Athira Pharma Chart |
1 Month Athira Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
